RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Lowers Price Target to $347
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and lowered the price target from $350 to $347.
November 07, 2023 | 6:23 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
RBC Capital has maintained its 'Sector Perform' rating on Vertex Pharmaceuticals and lowered the price target from $350 to $347.
The lowering of the price target by RBC Capital indicates a slightly less optimistic outlook for Vertex Pharmaceuticals. This could potentially lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100